Literature DB >> 11503107

Decisions regarding resuscitation of the extremely premature infant and models of best interest.

S R Leuthner1.   

Abstract

Differences concerning the care of an extremely premature infant may stem from alternative points of view on how to determine the infant's best interest. These alternatives are illustrated by differences between recently published statements by the American Academy of Pediatrics (AAP) Committee on Fetus and Newborn (COFN) and the Committee on Bioethics (COB). The statements agree that a goal of neonatal medicine is to minimize both under- and overtreatment of the extremely premature infant, and advocate that the decision-making process ought to be based on the concept of the premature infant's best interest. However, the two AAP Committees appear to diverge in how they operationalize the concept of an infant's best interest. The COFN adopts a process consistent with an "expertise" model of best interest, while the COB process is consistent with a "negotiated" model. In the "expertise" model, medical re-evaluation of the infant's status, the best outcome data available, and the treating physician's best medical judgment determine best interest. This model limits parental and societal input, and can lead a physician to act paternalistically. In the "negotiated" model, best interest is determined by outcome data and physician assessment, as well as the moral value of an outcome. This model maximizes parental input, accepts physicians as moral agents, and respects social influence in a decision. It is important to clarify one's model of best interest to help understand the differences of opinion regarding decisions based on best interest. The negotiated model of best interest is a more ethically appropriate model to approach decision making.

Entities:  

Mesh:

Year:  2001        PMID: 11503107     DOI: 10.1038/sj.jp.7200523

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  8 in total

1.  Measuring Health-Related Quality of Life in Pediatric Neurology.

Authors:  Monica E Lemmon; Hanna E Huffstetler; Bryce B Reeve
Journal:  J Child Neurol       Date:  2020-06-04       Impact factor: 1.987

2.  International variations in application of the best-interest standard across the age spectrum.

Authors:  N Laventhal; A A E Verhagen; T W R Hansen; E Dempsey; P G Davis; G A Musante; A Wiles; W Meadow; A Janvier
Journal:  J Perinatol       Date:  2016-10-13       Impact factor: 2.521

3.  A prospective study of maternal preference for indomethacin prophylaxis versus symptomatic treatment of a patent ductus arteriosus in preterm infants.

Authors:  Khalid AlFaleh; Eman Alluwaimi; Ahlam AlOsaimi; Sheikha Alrajebah; Bashayer AlOtaibi; Fatima AlRasheed; Turki AlKharfi; Bosco Paes
Journal:  BMC Pediatr       Date:  2015-04-22       Impact factor: 2.125

4.  Ethical issues in the treatment of extremely low birth weight neonates.

Authors:  Aleksandra Doronjski; Vesna Stojanović
Journal:  Croat Med J       Date:  2016-08-31       Impact factor: 1.351

5.  Exploring implicit bias in the perceived consequences of prematurity amongst health care providers in North Queensland - a constructivist grounded theory study.

Authors:  Susan Ireland; Robin Ray; Sarah Larkins; Lynn Woodward
Journal:  BMC Pregnancy Childbirth       Date:  2021-01-13       Impact factor: 3.007

6.  Neonatologists' Resuscitation Decisions at Birth for Extremely Premature Infants. A Belgian Qualitative Study.

Authors:  Alice Cavolo; Bernadette Dierckx de Casterlé; Gunnar Naulaers; Chris Gastmans
Journal:  Front Pediatr       Date:  2022-03-24       Impact factor: 3.418

Review 7.  The theorisation of 'best interests' in bioethical accounts of decision-making.

Authors:  Giles Birchley
Journal:  BMC Med Ethics       Date:  2021-06-01       Impact factor: 2.652

Review 8.  Ethical Issues around Death and Withdrawal of Life Support in Neonatal Intensive Care.

Authors:  Stuti Pant
Journal:  Indian J Pediatr       Date:  2021-06-18       Impact factor: 1.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.